Michael James Moser

This inventor holds 18 USPTO granted patents and 6 published patent applications, plus 5 CIPO patents and 4 EPO patents, primarily in Influenza Research. Top assignees: Flugen, Inc., Luminex Corporation, Eragen Biosciences, Inc.. Active years: 2009-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael James Moser. Retrieved from https://idiyas.com/inventor/michael-james-moser

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 6)

% Patents Active = 72.2

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 2.2

ph-index = 3

Forward Citations = 39(Granted Patents)

Company Filing History:

Eragen Biosciences, Inc.

patents

Years Active: 2009-2026

Loading Chart...

Areas of Expertise:

Vaccine

Influenza Virus

Nucleic Acid Detection

Immunogenic Compositions

Virus Backbone

Polymerase Inhibitor

Viral Mutants

RNA Quantification

Nucleic Acid Amplification

Detection Methods

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12728160 - VACCINE USING M2/BM2-DEFICIENT INFLUENZA VECTORS (2026-09-08),

2. 12616745 - INFLUENZA VIRUS BACKBONE (2026-05-05),

3. 12390519 - Influenza b virus mutants and uses therefor (2025-08-19),

4. 12311020 - Immunogenic compositions against influenza (2025-05-27),

5. 11980662 - Influenza virus vectors and uses therefor (2024-05-14),

6. 11529409 - Influenza B virus mutants and uses therefor (2022-12-20),

7. 11344616 - Immunogenic compositions against influenza (2022-05-31),

8. 11253584 - Influenza virus vectors and uses therefor (2022-02-22),

9. 10500267 - Influenza virus vectors and uses therefor (2019-12-10),

10. 10385412 - Methods for detection and typing of nucleic acids (2019-08-20),

11. 9757446 - Influenza virus vectors and uses therefor (2017-09-12),

12. 9562261 - Methods for detection and typing of nucleic acids (2017-02-07),

13. 9249455 - Methods for detection and quantification of small RNA (2016-02-02),

14. 8936913 - Methods for detection and typing of nucleic acids (2015-01-20),

15. 8313932 - Polymerase inhibitor and method of using same (2012-11-20),

Title: The Innovations of Michael James Moser

Introduction

Michael James Moser is a prominent inventor based in Madison, Wisconsin. He has made significant contributions to the field of virology, particularly in the development of mutant influenza viruses. With a total of 16 patents to his name, Moser's work has the potential to impact vaccine development and public health.

Latest Patents

Moser's latest patents include groundbreaking work on influenza B virus mutants and their uses. One of his patents discloses compositions and methods related to mutant viruses, specifically mutant influenza viruses. These mutant viruses include a mutant BM2 sequence, which is useful in immunogenic compositions, such as vaccines. Additionally, he has developed immunogenic compositions against influenza, which involve mutant M2 sequences and mutant BM2 sequences. These innovations are aimed at creating quadrivalent vaccines and improving methods for propagating viral mutants.

Career Highlights

Throughout his career, Moser has worked with notable companies such as Flugen, Inc. and Luminex Corporation. His expertise in virology and vaccine development has positioned him as a key figure in the industry. His contributions have been instrumental in advancing the understanding and treatment of influenza.

Collaborations

Moser has collaborated with esteemed colleagues, including Yasuko Hatta and Pamuk Bilsel. These partnerships have fostered innovation and have been crucial in the development of his patented technologies.

Conclusion

Michael James Moser's work in the field of virology and his numerous patents highlight his significant contributions to vaccine development. His innovations have the potential to enhance public health and improve immunization strategies against influenza.

Profile summary based on public USPTO records.